Leona Davis

About

Leona Davis is a faculty member at the College of Education at the University of Arizona. Her professional journey includes teaching in K-12 schools, designing and building water harvesting systems, managing food security programs at the Community Food Bank of Southern Arizona, and starting Earth Grant, a leadership development and paid internship program for University of Arizona undergraduates pursuing environmental careers. Currently, she manages interdisciplinary environmental graduate education programs with the Arizona Institute for Resilience. Her research interests focus on the intersections of environmental education, leadership development education, culture and identity, and the design and evaluation of equitable and inclusive educational programs. Her work has been published in journals such as Environmental Health Perspectives, Citizen Science Theory and Practice, and the International Journal of Environmental Research and Public Health.

Research topics

• Medicine
• Internal medicine
• Pharmacology
• Oncology
• Gastroenterology

Selected publications

• Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma

  Clinical Cancer Research · 2019-01-11 · 152 citations

  articleOpen access

  PURPOSE: Everolimus inhibits the mTOR, activating cytoprotective autophagy. Hydroxychloroquine inhibits autophagy. On the basis of preclinical data demonstrating synergistic cytotoxicity when mTOR inhibitors are combined with an autophagy inhibitor, we launched a clinical trial of combined everolimus and hydroxychloroquine, to determine its safety and activity in patients with clear-cell renal cell carcinoma (ccRCC). PATIENTS AND METHODS: Three centers conducted a phase I/II trial of everolimus…

  PublisherOA PDFDOI

• A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2– Metastatic Breast Cancer

  International Journal of Breast Cancer · 2020-06-20 · 76 citations

  reviewOpen accessSenior author

  PIK3CA mutation frequency varies among breast cancer (BC) subtypes. Recent evidence suggests combination therapy with the PI3K inhibitor (PI3Ki) alpelisib and endocrine therapy (ET) improves response rates and progression-free survival (PFS) in PIK3CA -mutant, hormone receptor positive (HR+) BC versus ET alone; thus, better understanding the clinical and epidemiologic elements of these mutations is warranted. This systematic review characterizes the PIK3CA mutation epidemiology, type of testing…

  PublisherOA PDFDOI

• A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR+/HER2− Metastatic Breast Cancer

  Clinical Breast Cancer · 2019-09-10 · 59 citations

  reviewSenior author
  PublisherDOI

• PD-1 Inhibition Achieves a Complete Metabolic Response in a Patient with Malignant Peripheral Nerve Sheath Tumor

  Cancer Immunology Research · 2019-08-05 · 32 citations

  article1st authorCorresponding

  High-grade malignant peripheral nerve sheath tumors (MPNST) have a poor prognosis with limited responsiveness to systemic therapy. We document a case of a complete metabolic response to pembrolizumab monotherapy in metastatic disease. Tumor molecular profiling identified programmed-death ligand-1 (PD-L1) positivity. This characteristic provided a rationale for immune-checkpoint therapy. Treatment with pembrolizumab resulted in a complete metabolic response after four cycles of therapy. Patients…

  PublisherDOI

• The relationship of vancomycin 24-hour AUC and trough concentration

  American Journal of Health-System Pharmacy · 2021-11-27 · 13 citations

  article

  PURPOSE: Prior to the 2020 release of a joint consensus guideline on monitoring of vancomycin therapy for serious methicillin-resistant Staphylococcus aureus (MRSA) infections, clinicians had escalated vancomycin doses for 2 decades while targeting trough concentrations of 15 to 20 µg/mL, leading to an increased frequency of nephrotoxicity. For MRSA infections, the 2020 guideline recommends adjusting doses to achieve a 24-hour area under the concentration-time curve (AUC) of 400 to 600 µg · h/mL…

  PublisherDOI

Frequent coauthors

• Ravi K. Amaravadi

  59 shared

• Peter J. O’Dwyer

  University of Pennsylvania

  40 shared

• Yunyoung C Chang

  Union Theological Seminary

  36 shared

• Kay-See Tan

  California University of Pennsylvania

  33 shared

• Daniel F. Heitjan

  Southern Methodist University

  33 shared

• Fabio Girardi

  Istituto Oncologico Veneto

  31 shared

• Reshma Rangwala

  30 shared

• Andrea B. Troxel

  Harvard University

  29 shared

Similar researchers at University of Arizona

• Jeremy Garciah-129
• Jermaine Williamsh-35
• Rao Xiongh-29